Rifat Pamucku

Dr. Pamukcu has extensive experience in pharmaceuticals and drug development, with a particular focus on oncology. He currently serves as the President and CEO of Midway Pharmaceuticals. He was also a co-founder, Director, and CSO of Cell Pathways (NASDAQ: CLPA, acquired by OSI Pharmaceuticals), where he directed the basic science, preclinical drug development, clinical research, regulatory programs, and various aspects of chemical scale-up and manufacturing, and raised over $140 million of investment capital. Dr. Pamukcu has been a member of the Advisory Council to the National Prostate Cancer Coalition, the GI Oncology Task Force of the American Gastroenterological Association, Executive Steering Committee of the Gastroenterology Research Group, and Scientific Advisory Board of the Hereditary Colon Cancer Association. Since 1985, Dr. Pamukcu has authored or co-authored over 110 journal articles, book chapters, and abstracts in the fields of gastroenterology, cancer, cancer chemoprevention, and signal transduction systems. He is an inventor on over 280 issued or pending patents in the areas of drug discovery and development of agents for cancer prevention, cancer chemotherapeutics, and inflammatory bowel disease.